PDCD1 and cancer: Therefore, we assume the combination of anti-PD-1 therapy towards malignant tumors with targeting lipid metabolism of TAMs might selectively strike M2-like macrophages without impairing M1-like macrophages to strengthen the effectiveness and sensibility of treatment.